What is Surgical Science Sweden AB (publ)?
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally.
SUSRF · Verdict
Moderate reward · low risk
SUSRF stands out on balance sheet and valuation, but watch the growth signal.
Based on 88% data coverage
SUSRF · Verdict
Current ratio 4.07
P/E 10.3×
Top decile vs peers
Rev +7.2% CAGR · earnings -29.2%
Model-based scoring. For information only — not financial advice.
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 144.91M, and a P/E ratio of 18.9x.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.